RxDoctor Payments Data

Michael Lawson, MD

Internal Medicine · Kearney, NENPI 1205819455

Payments from drug & device makers

$359in general payments, 2019–2025

Across 21 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$199
  • Pfizer$55
  • Abbott$32
  • Astellas Pharma US Inc$26
  • Sanofi$21
  • Novo Nordisk$14
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$359100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$359 in reported general payments places this provider in the 65th percentile of 570 internal medicine providers in Nebraska.

See all internal medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$71,223
Medicare patients
389
Services billed
1,008

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide99$122,162
EliquisApixaban99$61,998
XareltoRivaroxaban46$40,718
TrulicityDulaglutide32$35,758
MounjaroTirzepatide24$25,444
Tresiba Flextouch U-100Insulin Degludec48$24,277
Xultophy 100-3.6Insulin Degludec/Liraglutide16$20,822
MyrbetriqMirabegron54$17,737
FarxigaDapagliflozin Propanediol30$16,631
JardianceEmpagliflozin15$15,990
Tresiba Flextouch U-200Insulin Degludec25$15,694
Fiasp FlextouchInsulin Aspart (Niacinamide)24$12,862
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt18$12,160
LunestaEszopiclone11$11,238
JanuviaSitagliptin Phosphate16$11,068

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6$14$142,984115 claims
PfizerEliquis$55$61,99899 claims
Astellas Pharma US IncMyrbetriq$26$17,73754 claims
AbbVieSynthroid$199$4,13749 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 570 internal medicine providers in Nebraska.

Other internal medicine in Kearney

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →